Distinguished in Evans Syndrome

Isabelle Pellier

Angers, FR 
Distinguished in Evans Syndrome
Angers, FR 
OverviewLocationsClinical Research

Overview

Isabelle Pellier practices in Angers, France. Ms. Pellier is rated as a Distinguished expert by MediFind in the treatment of Evans Syndrome. Her top areas of expertise are Evans Syndrome, Autoimmune Hemolytic Anemia, Primary Immunodeficiency (PID), Splenectomy, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 109 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles in the study of Evans Syndrome.

Gender
Female

Locations

Angers, France
Other Locations
Paris, France
France
Amiens, France
Poitiers, 86000, France
Saint-jean-saint-germain, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2024
Intervention Type: Drug
Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification
Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification
Enrollment Status: Completed
Publish Date: December 01, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial
Enrollment Status: Terminated
Publish Date: March 01, 2023
Intervention Type: Drug
Study Drugs: Hydroxychloroquine, Lopinavir, Ritonavir
Study Phase: Phase 3
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency Diseases
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency Diseases
Enrollment Status: Completed
Publish Date: January 11, 2023
Intervention Type: Biological
Study Phase: Phase 4
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
Enrollment Status: Completed
Publish Date: August 29, 2022
Intervention Type: Drug
Study Drugs: Velbe+Bleomycin+Cisplatin, Vepeside+Ifosfamide+Cisplatin
Study Phase: Phase 2
Phase I Study of Fluvastatin-Celebrex Association for Optico-chiasmatic Low Grade Gliomas and High Grade Gliomas Localized Outside the Brainstem, Relapsed or Refactory, in Children or Young Adults
Phase I Study of Fluvastatin-Celebrex Association for Optico-chiasmatic Low Grade Gliomas and High Grade Gliomas Localized Outside the Brainstem, Relapsed or Refactory, in Children or Young Adults
Enrollment Status: Completed
Publish Date: February 10, 2022
Intervention Type: Drug
Study Drugs: Fluvastatine, Celebrex
Study Phase: Phase 1
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Enrollment Status: Completed
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of the Clinical Utility and Cost Effectiveness Ratio of Generalized Neonatal Screening for Severe Combined Immunodeficiencies (SCID) by Quantification of TRECs on Guthrie Cards
Evaluation of the Clinical Utility and Cost Effectiveness Ratio of Generalized Neonatal Screening for Severe Combined Immunodeficiencies (SCID) by Quantification of TRECs on Guthrie Cards
Enrollment Status: Completed
Publish Date: July 24, 2018
Intervention Type: Biological
Study Phase: Not Applicable
View 7 Less Clinical Trials

109 Total Publications

Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: A propensity score-matched study.
Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: A propensity score-matched study.
Journal: Blood advances
Published: June 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pellier's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile